Jeffrey A. Rona - 23 Feb 2026 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)

Reporting relationship: CBFO
Issuer ticker: OVID
Reported as of: 23 Feb 2026
Net transaction value: -$12,384
SEC form: 4
Accepted by SEC: 02 Mar 2026, 16:30:09 UTC
Prior SEC filing: 28 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Jeffrey Rona

Key filing fact

Jeffrey A. Rona filed Form 4 for Ovid Therapeutics Inc. (OVID) on 02 Mar 2026.

Key facts

This page summarizes Jeffrey A. Rona's Form 4 filing for Ovid Therapeutics Inc. (OVID).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Mar 2026, 16:30.

Change

Previous filing in this sequence was filed on 28 Feb 2025.
Current net transaction value: -$12,384.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001311404 Primary reporting owner

Rona Jeffrey A

Relationship: CBFO
Address: C/O OVID THERAPEUTICS INC., 441 NINTH AVENUE, NEW YORK
Signature: /s/ Jeffrey Rona
Signature date: 02 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OVID transaction

Common Stock

Sale

Transaction value: $12,384
Shares: -8,541
Change %: -8.8%
Price: $1.45
Shares after: 88,188
Date: 23 Feb 2026
Ownership: Direct
Footnotes: F1, F2, F3

OVID transaction

Common Stock

Award

Transaction value: $0
Shares: +68,125
Change %: +77%
Price: $0.000000
Shares after: 156,313
Date: 26 Feb 2026
Ownership: Direct
Footnotes: F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OVID transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +408,750
Change %
Price: $0.000000
Shares after: 408,750
Date: 26 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 408,750
Exercise price: $1.65
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

Footnote F2

The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.45 to $1.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

Includes 28,756 shares acquired under the Issuer's employee stock purchase plan.

Footnote F4

Represents a restricted stock unit ("RSU") award. The RSUs will vest in three equal annual installments commencing on February 20, 2027, subject to the Reporting Person's continuous service through each such vesting date.

Footnote F5

Each RSU represents a contingent right to receive one share of Common Stock.

Footnote F6

The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2026, subject to the Reporting Person's continued services through each such date.